InfuSystem Holdings, Inc. (INFU)
XASE:INFU
Want to see INFU full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.11Last Year’s EPS
0.12Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 07, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call balanced meaningful operational and financial progress with near-term headwinds. Positives include steady adjusted EBITDA (~$6.3M–$6.4M), improved gross margins, strong liquidity ($57M), rapid wound care growth (≈112% YoY to $2.1M), and a successful ERP go-live that should drive multi-quarter benefits. Offsetting these are GAAP revenue pressure from the GE Healthcare contract restructuring (quarterly reduction of ~$1.6M and an annualized ~$7.1M impact), a 17% decline in Device Solutions revenue, ERP stabilization costs and short-term cash flow/working capital pressures, and the setback on Chemo Mouthpiece coding. Overall, the company appears to be navigating a deliberate transition (mix shift toward higher-margin services and wound care) while absorbing one-time and near-term costs associated with ERP and contract restructurings.Company Guidance
Revenue (Pro Forma) Growth
Reported Q1 FY2026 net revenue of $33.7M; GAAP revenue declined ~ $1.0M (3% YoY), but on a pro forma basis (adjusting for GE Healthcare contract restructuring) revenue grew 1.7% YoY.
Strong Adjusted EBITDA and Margin Expansion
Generated approximately $6.3M–$6.4M in adjusted EBITDA in Q1 FY2026, roughly in line with prior year, with adjusted EBITDA margin improving to 18.9% from 18.2% a year ago.
Gross Profit and Margin Improvement
Gross profit rose by $515K (3% YoY) to $19.7M, and gross margin increased by ~3.2% to just over 58% in the quarter.
Patient Services Growth
Patient services net revenue increased $1.3M (6.4% YoY), with oncology revenue up ~$450K (2.4% YoY) and field-based biomedical services (adjusted for GE) growing by nearly $600K, indicating traction replacing some lost contract volume.
Wound Care Acceleration
Wound care net revenue reached $2.1M (about 6% of total revenue) and grew nearly 112% YoY. Roughly 60% of that growth was driven by compression devices; company added a second compression device supplier (adjustable compression wraps) to broaden addressable market.
ERP Go-Live Milestone
Enterprise resource planning (ERP) system successfully went live March 1, 2026 after a 20-month project. Management reports successful go-live, integrated data/workflows, and expects multi-faceted benefits (productivity, pricing visibility, device utilization, working capital optimization) as stabilization and enhancements proceed.
Device Solutions Margin Improvement
Device Solutions gross margin improved to 46.3% (up 3.4% YoY) and device services gross margin increased over 7% due to mix shift away from the large GE contract toward smaller field service projects, which contributed incremental gross margin despite lower overall revenue.
Strong Liquidity and Conservative Leverage
Available liquidity totaled just over $57M as of March 31, 2026; net debt increased modestly by $1.1M in the quarter and net debt to adjusted EBITDA remained low at ~0.56x. Company maintains $20M drawn on a $75M revolver with a favorable fixed-rate swap at 3.8% through April 2028.
Share Repurchase Activity
Repurchased approximately 800,000 common shares during the quarter under its authorization, signaling confidence in the business and capital allocation flexibility.
INFU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INFU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $7.58 | $8.60 | +13.46% |
Nov 04, 2025 | $10.40 | $9.46 | -9.04% |
Aug 05, 2025 | $5.85 | $6.07 | +3.76% |
May 08, 2025 | $4.75 | $5.47 | +15.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does InfuSystem Holdings, Inc. (INFU) report earnings?
InfuSystem Holdings, Inc. (INFU) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is InfuSystem Holdings, Inc. (INFU) earnings time?
InfuSystem Holdings, Inc. (INFU) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INFU EPS forecast?
INFU EPS forecast for the fiscal quarter 2026 (Q2) is 0.11.